Industry welcomes EU moves to improve orphan drug access
This article was originally published in Scrip
The biopharmaceutical industry has welcomed moves by the European Commission to set up a new EU rare diseases expert committee with industry representation, and has given its backing to calls for a new body to be established at the European Medicines Agency to assess the added value represented by new orphan drugs.
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.